Member Info for Benharper

Touk, you come across as stupid, wilfully stupid or delusional. I doubt non of these are what you set out to do. You’ve tried to infer in the past that I’m ‘angry’ with you and what you say, but it’s not that. I cringe really because it’s embarrassing. Stop it.

No, you’re ok Wyn, I don’t need to predict/manipulate the minutiae of RNS timelines to support a trading position.

Not pedantic at all, just pointing out the subtle ways that the bore and eggy fud. I don’t include Touk because he’s not as capable. And why is it desperate of me to point that out? I’m not desperate. Cool as a cucumber. You’re the guys plaguing an investment board on a share you’re not invested in. That’s desperate.

The slight warping of words is interesting pubbore.

‘Expected imminently’ Avacta

‘Expected to be imminent’ Pubbore

A subtle alteration by you, and fair play it does and an element of doubt. It’s also false. A lie one could call it.

Her 2 cancers being added suggests Merk and Keytruda tie up to me.

I think closer to mid summer/autumn when P1b is done. Probably a nice taster with final P1a results in one of the spring conferences.

Sorry Geeman, I was replying to Touk

‘Corporate consultant has paying hobby shocker’

Have you read the thread? It’s about what is happening to STS going forward, referring to the current corporate deck and it’s omission from the timelines.

Keeping it under the radar could be the one atm. Given Avactas current funding, to be proposing putting three indications through P2 might draw criticism and seem ambitious.

Don’t know, could it be partnered or licensed? It would seem strange and cruel to drop it if it performs well in P1b. What do you think?

Ish. Interest will build from P1b onwards ..

No it’s not. It will partner after p1b and be sold halfway through p2. Almost 0% chance it goes all the way. It’ll get funding and get on the Nasdaq. Most of these adc type companies selling for billions have 100 of millions in the bank when they are taken over. Avacta will have to by that point .

In the big scheme of things, after P1b, so mid year, is quiet soon

Perhaps, once patients are enrolled the trial can be seen to be underway..

Indeed, when it comes down to it most of us are laymen trying to make sense of professions in one way or another here.

Okay I get it now there’s 1 partial response, the minor responses don’t qualify so it’s a 10% response rate. Which sounds not that great to a layman. But when you dig a bit deeper the partial responses are also significant, in this setting/indication. Sort should have probably worked this out in my head rather than on the board!

Yes I have, what I mean is what does the 10% response rate refer too? There were 6 out of 10 that had a response. Responses varied the lowest of which was 10% shrinkage. I just don’t understand the headline to the article?!

Have I got the wrong end of the stick or does the headline make no sense?

Which views? They change like the wind, according to your trading position. Your post yesterday demonstrated this. Years until anything meaningful. I’d say 6 months. Anyway I’m off to work. Enjoy carping on here indefinitely.